{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T10:53:45Z","timestamp":1793962425780,"version":"4.8.0"},"reference-count":153,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T00:00:00Z","timestamp":1612483200000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006692","name":"Universit\u00e0 degli Studi di Torino","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006692","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Opinion statement<\/jats:title><jats:p>Heart failure (HF) is increasingly recognized as the major complication of chemotherapy regimens. Despite the development of modern targeted therapies such as monoclonal antibodies, doxorubicin (DOXO), one of the most cardiotoxic anticancer agents, still remains the treatment of choice for several solid and hematological tumors. The insurgence of cardiotoxicity represents the major limitation to the clinical use of this potent anticancer drug. At the molecular level, cardiac side effects of DOXO have been associated to mitochondrial dysfunction, DNA damage, impairment of iron metabolism, apoptosis, and autophagy dysregulation. On these bases, the antioxidant and iron chelator molecule, dexrazoxane, currently represents the unique FDA-approved cardioprotectant for patients treated with anthracyclines.<\/jats:p><jats:p>A less explored area of research concerns the impact of DOXO on cardiac metabolism. Recent metabolomic studies highlight the possibility that cardiac metabolic alterations may critically contribute to the development of DOXO cardiotoxicity. Among these, the impairment of oxidative phosphorylation and the persistent activation of glycolysis, which are commonly observed in response to DOXO treatment, may undermine the ability of cardiomyocytes to meet the energy demand, eventually leading to energetic failure. Moreover, increasing evidence links DOXO cardiotoxicity to imbalanced insulin signaling and to cardiac insulin resistance. Although anti-diabetic drugs, such as empagliflozin and metformin, have shown interesting cardioprotective effects in vitro and in vivo in different models of heart failure, their mechanism of action is unclear, and their use for the treatment of DOXO cardiotoxicity is still unexplored.<\/jats:p><jats:p>This review article aims at summarizing current evidence of the metabolic derangements induced by DOXO and at providing speculations on how key players of cardiac metabolism could be pharmacologically targeted to prevent or cure DOXO cardiomyopathy.<\/jats:p>","DOI":"10.1007\/s11864-020-00812-1","type":"journal-article","created":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T21:04:43Z","timestamp":1612818283000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":86,"title":["Metabolic Aspects of Anthracycline Cardiotoxicity"],"prefix":"10.1007","volume":"22","author":[{"given":"Michele","family":"Russo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Della Sala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Gabriele","family":"Tocchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo Ettore","family":"Porporato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1193-5296","authenticated-orcid":false,"given":"Alessandra","family":"Ghigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,5]]},"reference":[{"issue":"25","key":"812_CR1","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.2174\/092986709788803312","volume":"16","author":"C Carvalho","year":"2009","unstructured":"Carvalho C, Santos RX, Cardoso S, Correia S, Oliveira PJ, Santos MS, et al. Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem. 2009;16(25):3267\u201385. https:\/\/doi.org\/10.2174\/092986709788803312.","journal-title":"Curr Med Chem"},{"issue":"6","key":"812_CR2","first-page":"670","volume":"19","author":"RB Weiss","year":"1992","unstructured":"Weiss RB. The anthracyclines: will we ever find a better doxorubicin? Semin Oncol. 1992;19(6):670\u201386.","journal-title":"Semin Oncol"},{"issue":"2","key":"812_CR3","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s12012-007-0015-3","volume":"7","author":"H Cortes-Funes","year":"2007","unstructured":"Cortes-Funes H, Coronado C. Role of anthracyclines in the era of targeted therapy. Cardiovasc Toxicol. 2007;7(2):56\u201360. https:\/\/doi.org\/10.1007\/s12012-007-0015-3.","journal-title":"Cardiovasc Toxicol"},{"issue":"1\u20132","key":"812_CR4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1023\/a:1007094214460","volume":"207","author":"PK Singal","year":"2000","unstructured":"Singal PK, Li T, Kumar D, Danelisen I, Iliskovic N. Adriamycin-induced heart failure: mechanism and modulation. Mol Cell Biochem. 2000;207(1\u20132):77\u201386. https:\/\/doi.org\/10.1023\/a:1007094214460.","journal-title":"Mol Cell Biochem"},{"issue":"22","key":"812_CR5","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","volume":"131","author":"D Cardinale","year":"2015","unstructured":"Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131(22):1981\u20138. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.013777.","journal-title":"Circulation."},{"issue":"5","key":"812_CR6","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/s11886-013-0362-6","volume":"15","author":"A Colombo","year":"2013","unstructured":"Colombo A, Cipolla C, Beggiato M, Cardinale D. Cardiac toxicity of anticancer agents. Curr Cardiol Rep. 2013;15(5):362. https:\/\/doi.org\/10.1007\/s11886-013-0362-6.","journal-title":"Curr Cardiol Rep"},{"issue":"4","key":"812_CR7","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.ccl.2019.07.002","volume":"37","author":"TD Ryan","year":"2019","unstructured":"Ryan TD, Nagarajan R, Godown J. Cardiovascular toxicities in pediatric cancer survivors. Cardiol Clin. 2019;37(4):533\u201344. https:\/\/doi.org\/10.1016\/j.ccl.2019.07.002.","journal-title":"Cardiol Clin"},{"key":"812_CR8","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3389\/fphys.2018.00167","volume":"9","author":"G Varricchi","year":"2018","unstructured":"Varricchi G, Ameri P, Cadeddu C, Ghigo A, Madonna R, Marone G, et al. Antineoplastic drug-induced cardiotoxicity: a redox perspective. Front Physiol. 2018;9:167. https:\/\/doi.org\/10.3389\/fphys.2018.00167.","journal-title":"Front Physiol"},{"issue":"9","key":"812_CR9","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.jacc.2014.06.1167","volume":"64","author":"P Vejpongsa","year":"2014","unstructured":"Vejpongsa P, Yeh ET. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am Coll Cardiol. 2014;64(9):938\u201345. https:\/\/doi.org\/10.1016\/j.jacc.2014.06.1167.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"812_CR10","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1172\/JCI72931","volume":"124","author":"Y Ichikawa","year":"2014","unstructured":"Ichikawa Y, Ghanefar M, Bayeva M, Wu R, Khechaduri A, Naga Prasad SV, et al. Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. J Clin Invest. 2014;124(2):617\u201330. https:\/\/doi.org\/10.1172\/JCI72931.","journal-title":"J Clin Invest"},{"issue":"18","key":"812_CR11","doi-asserted-by":"publisher","first-page":"8839","DOI":"10.1158\/0008-5472.CAN-07-1649","volume":"67","author":"YL Lyu","year":"2007","unstructured":"Lyu YL, Kerrigan JE, Lin CP, Azarova AM, Tsai YC, Ban Y, et al. Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res. 2007;67(18):8839\u201346. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-1649.","journal-title":"Cancer Res"},{"issue":"1","key":"812_CR12","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1074\/jbc.M109.070037","volume":"285","author":"S Kobayashi","year":"2010","unstructured":"Kobayashi S, Volden P, Timm D, Mao K, Xu X, Liang Q. Transcription factor GATA4 inhibits doxorubicin-induced autophagy and cardiomyocyte death. J Biol Chem. 2010;285(1):793\u2013804. https:\/\/doi.org\/10.1074\/jbc.M109.070037.","journal-title":"J Biol Chem"},{"issue":"28","key":"812_CR13","doi-asserted-by":"publisher","first-page":"46663","DOI":"10.18632\/oncotarget.16944","volume":"8","author":"N Koleini","year":"2017","unstructured":"Koleini N, Kardami E. Autophagy and mitophagy in the context of doxorubicin-induced cardiotoxicity. Oncotarget. 2017;8(28):46663\u201380. https:\/\/doi.org\/10.18632\/oncotarget.16944.","journal-title":"Oncotarget"},{"issue":"15","key":"812_CR14","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1089\/ars.2020.8019","volume":"32","author":"V Sala","year":"2020","unstructured":"Sala V, Della Sala A, Hirsch E, Ghigo A. Signaling pathways underlying anthracycline cardiotoxicity. Antioxid Redox Signal. 2020;32(15):1098\u2013114. https:\/\/doi.org\/10.1089\/ars.2020.8019.","journal-title":"Antioxid Redox Signal"},{"issue":"6","key":"812_CR15","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.cardfail.2016.04.008","volume":"22","author":"V Mercurio","year":"2016","unstructured":"Mercurio V, Pirozzi F, Lazzarini E, Marone G, Rizzo P, Agnetti G, et al. Models of heart failure based on the cardiotoxicity of anticancer drugs. J Card Fail. 2016;22(6):449\u201358. https:\/\/doi.org\/10.1016\/j.cardfail.2016.04.008.","journal-title":"J Card Fail"},{"issue":"21","key":"812_CR16","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1016\/0006-2952(80)90050-7","volume":"29","author":"E Goormaghtigh","year":"1980","unstructured":"Goormaghtigh E, Chatelain P, Caspers J, Ruysschaert JM. Evidence of a complex between adriamycin derivatives and cardiolipin: possible role in cardiotoxicity. Biochem Pharmacol. 1980;29(21):3003\u201310. https:\/\/doi.org\/10.1016\/0006-2952(80)90050-7.","journal-title":"Biochem Pharmacol"},{"issue":"17","key":"812_CR17","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","volume":"112","author":"SM Grundy","year":"2005","unstructured":"Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association\/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112(17):2735\u201352. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.105.169404.","journal-title":"Circulation."},{"issue":"8","key":"812_CR18","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41569-018-0044-6","volume":"15","author":"E Bertero","year":"2018","unstructured":"\u2022\u2022 Bertero E, Maack C. Metabolic remodelling in heart failure. Nat Rev Cardiol. 2018;15(8):457\u201370. https:\/\/doi.org\/10.1038\/s41569-018-0044-6 Broad overview of the physiological processes of cardiac energy metabolism and their pathological alterations in heart failure.","journal-title":"Nat Rev Cardiol"},{"issue":"9","key":"812_CR19","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1161\/CIRCRESAHA.117.311002","volume":"122","author":"RW McGarrah","year":"2018","unstructured":"\u2022 McGarrah RW, Crown SB, Zhang GF, Shah SH, Newgard CB. Cardiovascular metabolomics. Circ Res. 2018;122(9):1238\u201358. https:\/\/doi.org\/10.1161\/CIRCRESAHA.117.311002 Discuss the current state of metabolomics, one of the newer omics technologies, emerged as a powerful tool for understanding the metabolic changes that occur in heart failure and ischemic heart disease.","journal-title":"Circ Res"},{"issue":"35","key":"812_CR20","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1200\/JCO.2017.75.4648","volume":"35","author":"M Dreyling","year":"2017","unstructured":"Dreyling M, Santoro A, Mollica L, Leppa S, Follows GA, Lenz G, et al. Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma. J Clin Oncol : official journal of the American Society of Clinical Oncology. 2017;35(35):3898\u2013905. https:\/\/doi.org\/10.1200\/JCO.2017.75.4648.","journal-title":"J Clin Oncol : official journal of the American Society of Clinical Oncology"},{"issue":"10","key":"812_CR21","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.3324\/haematol.2013.086355","volume":"98","author":"Z Racil","year":"2013","unstructured":"Racil Z, Razga F, Drapalova J, Buresova L, Zackova D, Palackova M, et al. Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia. Haematologica. 2013;98(10):e124\u20136. https:\/\/doi.org\/10.3324\/haematol.2013.086355.","journal-title":"Haematologica."},{"issue":"12","key":"812_CR22","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1016\/j.leukres.2007.01.024","volume":"31","author":"M Breccia","year":"2007","unstructured":"Breccia M, Muscaritoli M, Gentilini F, Latagliata R, Carmosino I, Rossi Fanelli F, et al. Impaired fasting glucose level as metabolic side effect of nilotinib in non-diabetic chronic myeloid leukemia patients resistant to imatinib. Leuk Res. 2007;31(12):1770\u20132. https:\/\/doi.org\/10.1016\/j.leukres.2007.01.024.","journal-title":"Leuk Res"},{"issue":"19","key":"812_CR23","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1093\/jnci\/djs376","volume":"104","author":"NL Keating","year":"2012","unstructured":"Keating NL, O'Malley A, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst. 2012;104(19):1518\u201323. https:\/\/doi.org\/10.1093\/jnci\/djs376.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"812_CR24","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s10147-015-0891-7","volume":"21","author":"R Oka","year":"2016","unstructured":"Oka R, Utsumi T, Endo T, Yano M, Kamijima S, Kamiya N, et al. Effect of androgen deprivation therapy on arterial stiffness and serum lipid profile changes in patients with prostate cancer: a prospective study of initial 6-month follow-up. Int J Clin Oncol. 2016;21(2):389\u201396. https:\/\/doi.org\/10.1007\/s10147-015-0891-7.","journal-title":"Int J Clin Oncol"},{"key":"812_CR25","doi-asserted-by":"publisher","unstructured":"\u2022 Asnani A, Shi X, Farrell L, Lall R, Sebag IA, Plana JC, et al. Changes in citric acid cycle and nucleoside metabolism are associated with anthracycline cardiotoxicity in patients with breast cancer. J Cardiovasc Transl Res. 2019. https:\/\/doi.org\/10.1007\/s12265-019-09897-y Clinical study reporting the role in patients of early metabolic changes as insight into the mechanisms associated with the development of chemotherapy-associated cardiotoxicity.","DOI":"10.1007\/s12265-019-09897-y"},{"issue":"5","key":"812_CR26","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.3390\/molecules23051184","volume":"23","author":"R Zilinyi","year":"2018","unstructured":"\u2022\u2022 Zilinyi R, Czompa A, Czegledi A, Gajtko A, Pituk D, Lekli I, et al. The cardioprotective effect of metformin in doxorubicin-induced cardiotoxicity: the role of autophagy. Molecules. 2018;23(5):1184. https:\/\/doi.org\/10.3390\/molecules23051184 Examine the protective role of metformin and its effect on autophagy in doxorubicin-induced cardiotoxicity.","journal-title":"Molecules"},{"key":"812_CR27","doi-asserted-by":"publisher","unstructured":"\u2022 Oh CM, Cho S, Jang JY, Kim H, Chun S, Choi M, et al. Cardioprotective potential of an SGLT2 inhibitor against doxorubicin-induced heart failure. Korean Circ J. 2019;49(12):1183\u201395. https:\/\/doi.org\/10.4070\/kcj.2019.0180 First study reporting the cardioprotective effects of SGLT2 inhibitors in DOXO-induced HF in mice. Treatment with empagliflozin prevented the development of DOXO-cardiotoxicity by switching fuel consumption and activating autophagy.","DOI":"10.4070\/kcj.2019.0180"},{"issue":"1","key":"812_CR28","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s10565-006-0140-y","volume":"23","author":"JM Berthiaume","year":"2007","unstructured":"Berthiaume JM, Wallace KB. Adriamycin-induced oxidative mitochondrial cardiotoxicity. Cell Biol Toxicol. 2007;23(1):15\u201325. https:\/\/doi.org\/10.1007\/s10565-006-0140-y.","journal-title":"Cell Biol Toxicol"},{"issue":"4 Suppl 10","key":"812_CR29","first-page":"10","volume":"25","author":"C Myers","year":"1998","unstructured":"Myers C. The role of iron in doxorubicin-induced cardiomyopathy. Semin Oncol. 1998;25(4 Suppl 10):10\u20134.","journal-title":"Semin Oncol"},{"issue":"2","key":"812_CR30","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/0163-7258(90)90088-j","volume":"47","author":"HG Keizer","year":"1990","unstructured":"Keizer HG, Pinedo HM, Schuurhuis GJ, Joenje H. Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity. Pharmacol Ther. 1990;47(2):219\u201331. https:\/\/doi.org\/10.1016\/0163-7258(90)90088-j.","journal-title":"Pharmacol Ther"},{"issue":"8","key":"812_CR31","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1124\/dmd.105.004374","volume":"33","author":"DS Riddick","year":"2005","unstructured":"Riddick DS, Lee C, Ramji S, Chinje EC, Cowen RL, Williams KJ, et al. Cancer chemotherapy and drug metabolism. Drug Metab Dispos. 2005;33(8):1083\u201396. https:\/\/doi.org\/10.1124\/dmd.105.004374.","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"812_CR32","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1124\/mol.105.013383","volume":"68","author":"X Xu","year":"2005","unstructured":"Xu X, Persson HL, Richardson DR. Molecular pharmacology of the interaction of anthracyclines with iron. Mol Pharmacol. 2005;68(2):261\u201371. https:\/\/doi.org\/10.1124\/mol.105.013383.","journal-title":"Mol Pharmacol"},{"issue":"8","key":"812_CR33","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1021\/bi00537a001","volume":"21","author":"CE Myers","year":"1982","unstructured":"Myers CE, Gianni L, Simone CB, Klecker R, Greene R. Oxidative destruction of erythrocyte ghost membranes catalyzed by the doxorubicin-iron complex. Biochemistry. 1982;21(8):1707\u201312. https:\/\/doi.org\/10.1021\/bi00537a001.","journal-title":"Biochemistry."},{"issue":"23","key":"812_CR34","first-page":"8422","volume":"61","author":"G Minotti","year":"2001","unstructured":"Minotti G, Ronchi R, Salvatorelli E, Menna P, Cairo G. Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy. Cancer Res. 2001;61(23):8422\u20138.","journal-title":"Cancer Res"},{"issue":"3","key":"812_CR35","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1124\/mol.107.041335","volume":"73","author":"X Xu","year":"2008","unstructured":"Xu X, Sutak R, Richardson DR. Iron chelation by clinically relevant anthracyclines: alteration in expression of iron-regulated genes and atypical changes in intracellular iron distribution and trafficking. Mol Pharmacol. 2008;73(3):833\u201344. https:\/\/doi.org\/10.1124\/mol.107.041335.","journal-title":"Mol Pharmacol"},{"issue":"4","key":"812_CR36","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1124\/mol.63.4.849","volume":"63","author":"JC Kwok","year":"2003","unstructured":"Kwok JC, Richardson DR. Anthracyclines induce accumulation of iron in ferritin in myocardial and neoplastic cells: inhibition of the ferritin iron mobilization pathway. Mol Pharmacol. 2003;63(4):849\u201361. https:\/\/doi.org\/10.1124\/mol.63.4.849.","journal-title":"Mol Pharmacol"},{"issue":"2","key":"812_CR37","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.cell.2017.09.021","volume":"171","author":"BR Stockwell","year":"2017","unstructured":"Stockwell BR, Friedmann Angeli JP, Bayir H, Bush AI, Conrad M, Dixon SJ, et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017;171(2):273\u201385. https:\/\/doi.org\/10.1016\/j.cell.2017.09.021.","journal-title":"Cell."},{"issue":"1","key":"812_CR38","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13045-019-0720-y","volume":"12","author":"Y Mou","year":"2019","unstructured":"Mou Y, Wang J, Wu J, He D, Zhang C, Duan C, et al. Ferroptosis, a new form of cell death: opportunities and challenges in cancer. J Hematol Oncol. 2019;12(1):34. https:\/\/doi.org\/10.1186\/s13045-019-0720-y.","journal-title":"J Hematol Oncol"},{"issue":"11","key":"812_CR39","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1038\/mp.2017.171","volume":"22","author":"QZ Tuo","year":"2017","unstructured":"Tuo QZ, Lei P, Jackman KA, Li XL, Xiong H, Li XL, et al. Tau-mediated iron export prevents ferroptotic damage after ischemic stroke. Mol Psychiatry. 2017;22(11):1520\u201330. https:\/\/doi.org\/10.1038\/mp.2017.171.","journal-title":"Mol Psychiatry"},{"issue":"47","key":"812_CR40","doi-asserted-by":"publisher","first-page":"16836","DOI":"10.1073\/pnas.1415518111","volume":"111","author":"A Linkermann","year":"2014","unstructured":"Linkermann A, Skouta R, Himmerkus N, Mulay SR, Dewitz C, De Zen F, et al. Synchronized renal tubular cell death involves ferroptosis. Proc Natl Acad Sci U S A. 2014;111(47):16836\u201341. https:\/\/doi.org\/10.1073\/pnas.1415518111.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"812_CR41","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1073\/pnas.1821022116","volume":"116","author":"X Fang","year":"2019","unstructured":"\u2022\u2022 Fang X, Wang H, Han D, Xie E, Yang X, Wei J, et al. Ferroptosis as a target for protection against cardiomyopathy. Proc Natl Acad Sci U S A. 2019;116(7):2672\u201380. https:\/\/doi.org\/10.1073\/pnas.1821022116 First evidence that inhibition of Ferroptosis protects from heart dynsfuction.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"812_CR42","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1038\/nm.2919","volume":"18","author":"S Zhang","year":"2012","unstructured":"Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu YL, Liu LF, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012;18(11):1639\u201342. https:\/\/doi.org\/10.1038\/nm.2919.","journal-title":"Nat Med"},{"issue":"5","key":"812_CR43","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1200\/JCO.2005.02.3879","volume":"25","author":"CK Tebbi","year":"2007","unstructured":"Tebbi CK, London WB, Friedman D, Villaluna D, De Alarcon PA, Constine LS, et al. Dexrazoxane-associated risk for acute myeloid leukemia\/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J Clin Oncol. 2007;25(5):493\u2013500. https:\/\/doi.org\/10.1200\/JCO.2005.02.3879.","journal-title":"J Clin Oncol"},{"issue":"9","key":"812_CR44","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1111\/bph.13046","volume":"172","author":"S Deng","year":"2015","unstructured":"Deng S, Yan T, Nikolova T, Fuhrmann D, Nemecek A, Godtel-Armbrust U, et al. The catalytic topoisomerase II inhibitor dexrazoxane induces DNA breaks, ATF3 and the DNA damage response in cancer cells. Br J Pharmacol. 2015;172(9):2246\u201357. https:\/\/doi.org\/10.1111\/bph.13046.","journal-title":"Br J Pharmacol"},{"issue":"4","key":"812_CR45","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1200\/JCO.1997.15.4.1318","volume":"15","author":"SM Swain","year":"1997","unstructured":"Swain SM, Whaley FS, Gerber MC, Weisberg S, York M, Spicer D, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol. 1997;15(4):1318\u201332. https:\/\/doi.org\/10.1200\/JCO.1997.15.4.1318.","journal-title":"J Clin Oncol"},{"issue":"25","key":"812_CR46","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.2217\/fon-2018-0210","volume":"14","author":"P Reichardt","year":"2018","unstructured":"Reichardt P, Tabone MD, Mora J, Morland B, Jones RL. Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling. Future Oncol. 2018;14(25):2663\u201376. https:\/\/doi.org\/10.2217\/fon-2018-0210.","journal-title":"Future Oncol"},{"issue":"4","key":"812_CR47","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/pbc.25043","volume":"62","author":"AE Seif","year":"2015","unstructured":"Seif AE, Walker DM, Li Y, Huang YS, Kavcic M, Torp K, et al. Dexrazoxane exposure and risk of secondary acute myeloid leukemia in pediatric oncology patients. Pediatr Blood Cancer. 2015;62(4):704\u20139. https:\/\/doi.org\/10.1002\/pbc.25043.","journal-title":"Pediatr Blood Cancer"},{"key":"812_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.tox.2017.09.012","volume":"392","author":"J Bures","year":"2017","unstructured":"Bures J, Jirkovska A, Sestak V, Jansova H, Karabanovich G, Roh J, et al. Investigation of novel dexrazoxane analogue JR-311 shows significant cardioprotective effects through topoisomerase IIbeta but not its iron chelating metabolite. Toxicology. 2017;392:1\u201310. https:\/\/doi.org\/10.1016\/j.tox.2017.09.012.","journal-title":"Toxicology."},{"issue":"1","key":"812_CR49","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1124\/jpet.108.137604","volume":"326","author":"O Popelova","year":"2008","unstructured":"Popelova O, Sterba M, Simunek T, Mazurova Y, Guncova I, Hroch M, et al. Deferiprone does not protect against chronic anthracycline cardiotoxicity in vivo. J Pharmacol Exp Ther. 2008;326(1):259\u201369. https:\/\/doi.org\/10.1124\/jpet.108.137604.","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"812_CR50","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.freeradbiomed.2003.08.005","volume":"35","author":"BB Hasinoff","year":"2003","unstructured":"Hasinoff BB, Patel D, Wu X. The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin. Free Radic Biol Med. 2003;35(11):1469\u201379. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2003.08.005.","journal-title":"Free Radic Biol Med"},{"issue":"5","key":"812_CR51","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1124\/mol.51.5.842","volume":"51","author":"G Zanninelli","year":"1997","unstructured":"Zanninelli G, Glickstein H, Breuer W, Milgram P, Brissot P, Hider RC, et al. Chelation and mobilization of cellular iron by different classes of chelators. Mol Pharmacol. 1997;51(5):842\u201352. https:\/\/doi.org\/10.1124\/mol.51.5.842.","journal-title":"Mol Pharmacol"},{"issue":"6","key":"812_CR52","first-page":"683","volume":"53","author":"L Schroterova","year":"2004","unstructured":"Schroterova L, Kaiserova H, Baliharova V, Velik J, Gersl V, Kvasnickova E. The effect of new lipophilic chelators on the activities of cytosolic reductases and P450 cytochromes involved in the metabolism of anthracycline antibiotics: studies in vitro. Physiol Res. 2004;53(6):683\u201391.","journal-title":"Physiol Res"},{"key":"812_CR53","doi-asserted-by":"publisher","first-page":"101328","DOI":"10.1016\/j.redox.2019.101328","volume":"28","author":"G Miotto","year":"2020","unstructured":"Miotto G, Rossetto M, Di Paolo ML, Orian L, Venerando R, Roveri A, et al. Insight into the mechanism of ferroptosis inhibition by ferrostatin-1. Redox Biol. 2020;28:101328. https:\/\/doi.org\/10.1016\/j.redox.2019.101328.","journal-title":"Redox Biol"},{"issue":"5","key":"812_CR54","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060\u201372. https:\/\/doi.org\/10.1016\/j.cell.2012.03.042.","journal-title":"Cell."},{"issue":"3","key":"812_CR55","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1152\/physrev.00006.2004","volume":"85","author":"WC Stanley","year":"2005","unstructured":"Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev. 2005;85(3):1093\u2013129. https:\/\/doi.org\/10.1152\/physrev.00006.2004.","journal-title":"Physiol Rev"},{"issue":"5","key":"812_CR56","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1161\/CIRCHEARTFAILURE.112.000228","volume":"6","author":"L Zhang","year":"2013","unstructured":"Zhang L, Jaswal JS, Ussher JR, Sankaralingam S, Wagg C, Zaugg M, et al. Cardiac insulin-resistance and decreased mitochondrial energy production precede the development of systolic heart failure after pressure-overload hypertrophy. Circ Heart Fail. 2013;6(5):1039\u201348. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.112.000228.","journal-title":"Circ Heart Fail"},{"issue":"2","key":"812_CR57","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jacc.2007.10.021","volume":"51","author":"RM Witteles","year":"2008","unstructured":"Witteles RM, Fowler MB. Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options. J Am Coll Cardiol. 2008;51(2):93\u2013102. https:\/\/doi.org\/10.1016\/j.jacc.2007.10.021.","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"812_CR58","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1056\/NEJMoa072761","volume":"356","author":"SE Nissen","year":"2007","unstructured":"Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457\u201371. https:\/\/doi.org\/10.1056\/NEJMoa072761.","journal-title":"N Engl J Med"},{"issue":"12","key":"812_CR59","doi-asserted-by":"publisher","first-page":"H1693","DOI":"10.1152\/ajpheart.00854.2012","volume":"305","author":"H Taegtmeyer","year":"2013","unstructured":"Taegtmeyer H, Beauloye C, Harmancey R, Hue L. Insulin resistance protects the heart from fuel overload in dysregulated metabolic states. Am J Physiol Heart Circ Physiol. 2013;305(12):H1693\u20137. https:\/\/doi.org\/10.1152\/ajpheart.00854.2012.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"3","key":"812_CR60","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1128\/MCB.00983-10","volume":"31","author":"YC Long","year":"2011","unstructured":"Long YC, Cheng Z, Copps KD, White MF. Insulin receptor substrates Irs1 and Irs2 coordinate skeletal muscle growth and metabolism via the Akt and AMPK pathways. Mol Cell Biol. 2011;31(3):430\u201341. https:\/\/doi.org\/10.1128\/MCB.00983-10.","journal-title":"Mol Cell Biol"},{"key":"812_CR61","doi-asserted-by":"publisher","unstructured":"\u2022 Deidda M, Mercurio V, Cuomo A, Noto A, Mercuro G, Cadeddu DC. Metabolomic perspectives in antiblastic cardiotoxicity and cardioprotection. Int J Mol Sci. 2019;20(19):4928. https:\/\/doi.org\/10.3390\/ijms20194928 Recent overview that describes metabolomic approach as a potential and practical tool to investigate the impact of chemotherapy-induced cardiotoxicity.","DOI":"10.3390\/ijms20194928"},{"issue":"2","key":"812_CR62","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.febslet.2012.11.019","volume":"587","author":"S Arunachalam","year":"2013","unstructured":"Arunachalam S, Tirupathi Pichiah PB, Achiraman S. Doxorubicin treatment inhibits PPARgamma and may induce lipotoxicity by mimicking a type 2 diabetes-like condition in rodent models. FEBS Lett. 2013;587(2):105\u201310. https:\/\/doi.org\/10.1016\/j.febslet.2012.11.019.","journal-title":"FEBS Lett"},{"issue":"5","key":"812_CR63","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/jcsm.12104","volume":"7","author":"EA de Lima Junior","year":"2016","unstructured":"de Lima Junior EA, Yamashita AS, Pimentel GD, De Sousa LG, Santos RV, Goncalves CL, et al. Doxorubicin caused severe hyperglycaemia and insulin resistance, mediated by inhibition in AMPk signalling in skeletal muscle. J Cachexia Sarcopenia Muscle. 2016;7(5):615\u201325. https:\/\/doi.org\/10.1002\/jcsm.12104.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"10","key":"812_CR64","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.2967\/jnumed.117.191122","volume":"58","author":"M Bauckneht","year":"2017","unstructured":"\u2022\u2022 Bauckneht M, Ferrarazzo G, Fiz F, Morbelli S, Sarocchi M, Pastorino F, et al. Doxorubicin effect on myocardial metabolism as a prerequisite for subsequent development of cardiac toxicity: a translational (18)F-FDG PET\/CT observation. J Nucl Med. 2017;58(10):1638\u201345. https:\/\/doi.org\/10.2967\/jnumed.117.191122 Translational study that indicates basal cardiac metabolism as predictive factor doxorubicin-induced cardiotoxicity.","journal-title":"J Nucl Med"},{"issue":"4","key":"812_CR65","doi-asserted-by":"publisher","first-page":"713","DOI":"10.2967\/jnumed.117.206797","volume":"59","author":"G Sambuceti","year":"2018","unstructured":"Sambuceti G, Morbelli S, Cossu V, Marini C, Bauckneht M. Reply: doxorubicin effect on myocardial metabolism as a prerequisite for subsequent development of cardiac toxicity: are there unsuspected confounders? J Nucl Med. 2018;59(4):713\u20134. https:\/\/doi.org\/10.2967\/jnumed.117.206797.","journal-title":"J Nucl Med"},{"issue":"2\u20133","key":"812_CR66","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.tox.2010.01.019","volume":"270","author":"RA Carvalho","year":"2010","unstructured":"Carvalho RA, Sousa RP, Cadete VJ, Lopaschuk GD, Palmeira CM, Bjork JA, et al. Metabolic remodeling associated with subchronic doxorubicin cardiomyopathy. Toxicology. 2010;270(2\u20133):92\u20138. https:\/\/doi.org\/10.1016\/j.tox.2010.01.019.","journal-title":"Toxicology."},{"issue":"2","key":"812_CR67","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/j.1432-1033.1997.00259.x","volume":"246","author":"DG Hardie","year":"1997","unstructured":"Hardie DG, Carling D. The AMP-activated protein kinase--fuel gauge of the mammalian cell? Eur J Biochem. 1997;246(2):259\u201373. https:\/\/doi.org\/10.1111\/j.1432-1033.1997.00259.x.","journal-title":"Eur J Biochem"},{"issue":"2","key":"812_CR68","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1023\/B:REMD.0000021433.63915.bb","volume":"5","author":"DG Hardie","year":"2004","unstructured":"Hardie DG. AMP-activated protein kinase: a master switch in glucose and lipid metabolism. Rev Endocr Metab Disord. 2004;5(2):119\u201325. https:\/\/doi.org\/10.1023\/B:REMD.0000021433.63915.bb.","journal-title":"Rev Endocr Metab Disord"},{"issue":"3","key":"812_CR69","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1093\/cvr\/cvs134","volume":"95","author":"S Gratia","year":"2012","unstructured":"Gratia S, Kay L, Potenza L, Seffouh A, Novel-Chate V, Schnebelen C, et al. Inhibition of AMPK signalling by doxorubicin: at the crossroads of the cardiac responses to energetic, oxidative, and genotoxic stress. Cardiovasc Res. 2012;95(3):290\u20139. https:\/\/doi.org\/10.1093\/cvr\/cvs134.","journal-title":"Cardiovasc Res"},{"issue":"1","key":"812_CR70","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1038\/s41598-019-38986-w","volume":"9","author":"BF Bulten","year":"2019","unstructured":"Bulten BF, Sollini M, Boni R, Massri K, de Geus-Oei LF, van Laarhoven HWM, et al. Cardiac molecular pathways influenced by doxorubicin treatment in mice. Sci Rep. 2019;9(1):2514. https:\/\/doi.org\/10.1038\/s41598-019-38986-w.","journal-title":"Sci Rep"},{"issue":"1\u20132","key":"812_CR71","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/s0005-2736(02)00612-0","volume":"1567","author":"S Hrelia","year":"2002","unstructured":"Hrelia S, Fiorentini D, Maraldi T, Angeloni C, Bordoni A, Biagi PL, et al. Doxorubicin induces early lipid peroxidation associated with changes in glucose transport in cultured cardiomyocytes. Biochim Biophys Acta. 2002;1567(1\u20132):150\u20136. https:\/\/doi.org\/10.1016\/s0005-2736(02)00612-0.","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"812_CR72","doi-asserted-by":"publisher","first-page":"H37","DOI":"10.1152\/ajpheart.01057.2004","volume":"289","author":"M Tokarska-Schlattner","year":"2005","unstructured":"Tokarska-Schlattner M, Zaugg M, da Silva R, Lucchinetti E, Schaub MC, Wallimann T, et al. Acute toxicity of doxorubicin on isolated perfused heart: response of kinases regulating energy supply. Am J Physiol Heart Circ Physiol. 2005;289(1):H37\u201347. https:\/\/doi.org\/10.1152\/ajpheart.01057.2004.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"7","key":"812_CR73","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1172\/JCI29044","volume":"116","author":"YC Long","year":"2006","unstructured":"Long YC, Zierath JR. AMP-activated protein kinase signaling in metabolic regulation. J Clin Invest. 2006;116(7):1776\u201383. https:\/\/doi.org\/10.1172\/JCI29044.","journal-title":"J Clin Invest"},{"issue":"14","key":"812_CR74","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1136\/heartjnl-2013-303843","volume":"99","author":"J Nagendran","year":"2013","unstructured":"Nagendran J, Kienesberger PC, Pulinilkunnil T, Zordoky BN, Sung MM, Kim T, et al. Cardiomyocyte specific adipose triglyceride lipase overexpression prevents doxorubicin induced cardiac dysfunction in female mice. Heart. 2013;99(14):1041\u20137. https:\/\/doi.org\/10.1136\/heartjnl-2013-303843.","journal-title":"Heart."},{"issue":"6","key":"812_CR75","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1093\/emboj\/17.6.1688","volume":"17","author":"M Ponticos","year":"1998","unstructured":"Ponticos M, Lu QL, Morgan JE, Hardie DG, Partridge TA, Carling D. Dual regulation of the AMP-activated protein kinase provides a novel mechanism for the control of creatine kinase in skeletal muscle. EMBO J. 1998;17(6):1688\u201399. https:\/\/doi.org\/10.1093\/emboj\/17.6.1688.","journal-title":"EMBO J"},{"issue":"10","key":"812_CR76","doi-asserted-by":"publisher","first-page":"e74675","DOI":"10.1371\/journal.pone.0074675","volume":"8","author":"A Gupta","year":"2013","unstructured":"Gupta A, Rohlfsen C, Leppo MK, Chacko VP, Wang Y, Steenbergen C, et al. Creatine kinase-overexpression improves myocardial energetics, contractile dysfunction and survival in murine doxorubicin cardiotoxicity. PLoS One. 2013;8(10):e74675. https:\/\/doi.org\/10.1371\/journal.pone.0074675.","journal-title":"PLoS One"},{"issue":"6","key":"812_CR77","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/j.yjmcc.2012.03.006","volume":"52","author":"Y Octavia","year":"2012","unstructured":"Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJ, Moens AL. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol. 2012;52(6):1213\u201325. https:\/\/doi.org\/10.1016\/j.yjmcc.2012.03.006.","journal-title":"J Mol Cell Cardiol"},{"key":"812_CR78","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.freeradbiomed.2018.08.032","volume":"129","author":"D Liu","year":"2018","unstructured":"Liu D, Ma Z, Di S, Yang Y, Yang J, Xu L, et al. AMPK\/PGC1alpha activation by melatonin attenuates acute doxorubicin cardiotoxicity via alleviating mitochondrial oxidative damage and apoptosis. Free Radic Biol Med. 2018;129:59\u201372. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2018.08.032.","journal-title":"Free Radic Biol Med"},{"issue":"12","key":"812_CR79","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1038\/s41596-018-0076-8","volume":"13","author":"A Sharma","year":"2018","unstructured":"\u2022\u2022 Sharma A, McKeithan WL, Serrano R, Kitani T, Burridge PW, Del Alamo JC, et al. Use of human induced pluripotent stem cell-derived cardiomyocytes to assess drug cardiotoxicity. Nat Protoc. 2018;13(12):3018\u201341. https:\/\/doi.org\/10.1038\/s41596-018-0076-8 Assessment of a new biological platform to investigate the drug-induced cardiotoxicity in human induced pluripotent stem cell-derived cardiomyocytes.","journal-title":"Nat Protoc"},{"key":"812_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.taap.2018.04.009","volume":"348","author":"T Cunha-Oliveira","year":"2018","unstructured":"Cunha-Oliveira T, Ferreira LL, Coelho AR, Deus CM, Oliveira PJ. Doxorubicin triggers bioenergetic failure and p53 activation in mouse stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2018;348:1\u201313. https:\/\/doi.org\/10.1016\/j.taap.2018.04.009.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"7","key":"812_CR81","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.2337\/diabetes.51.7.2074","volume":"51","author":"N Musi","year":"2002","unstructured":"Musi N, Hirshman MF, Nygren J, Svanfeldt M, Bavenholm P, Rooyackers O, et al. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes. 2002;51(7):2074\u201381. https:\/\/doi.org\/10.2337\/diabetes.51.7.2074.","journal-title":"Diabetes."},{"key":"812_CR82","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.freeradbiomed.2012.09.009","volume":"57","author":"MC Asensio-Lopez","year":"2013","unstructured":"Asensio-Lopez MC, Sanchez-Mas J, Pascual-Figal DA, Abenza S, Perez-Martinez MT, Valdes M, et al. Involvement of ferritin heavy chain in the preventive effect of metformin against doxorubicin-induced cardiotoxicity. Free Radic Biol Med. 2013;57:188\u2013200. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2012.09.009.","journal-title":"Free Radic Biol Med"},{"issue":"21","key":"812_CR83","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1161\/CIRCULATIONAHA.118.037357","volume":"139","author":"T Kitani","year":"2019","unstructured":"\u2022\u2022 Kitani T, Ong SG, Lam CK, Rhee JW, Zhang JZ, Oikonomopoulos A, et al. Human-induced pluripotent stem cell model of trastuzumab-induced cardiac dysfunction in patients with breast cancer. Circulation. 2019;139(21):2451\u201365. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.037357 Evaluation of Trastuzumab-induced cardiotoxicity on human induced pluripotent stem cell-model derived from patients.","journal-title":"Circulation"},{"issue":"4","key":"812_CR84","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s10059-013-0169-8","volume":"36","author":"YK Choi","year":"2013","unstructured":"Choi YK, Park KG. Metabolic roles of AMPK and metformin in cancer cells. Mol Cell. 2013;36(4):279\u201387. https:\/\/doi.org\/10.1007\/s10059-013-0169-8.","journal-title":"Mol Cell"},{"issue":"6","key":"812_CR85","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/j.cell.2013.05.039","volume":"153","author":"C Lopez-Otin","year":"2013","unstructured":"Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153(6):1194\u2013217. https:\/\/doi.org\/10.1016\/j.cell.2013.05.039.","journal-title":"Cell."},{"issue":"2","key":"812_CR86","doi-asserted-by":"publisher","first-page":"e013754","DOI":"10.1161\/JAHA.119.013754","volume":"9","author":"JP Aboumsallem","year":"2020","unstructured":"\u2022\u2022 Aboumsallem JP, Moslehi J, de Boer RA. Reverse cardio-oncology: cancer development in patients with cardiovascular disease. J Am Heart Assoc. 2020;9(2):e013754. https:\/\/doi.org\/10.1161\/JAHA.119.013754 Recent overview on Heart Failure-associated factors inducing Cancer.","journal-title":"J Am Heart Assoc"},{"issue":"12","key":"812_CR87","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1002\/ejhf.1539","volume":"21","author":"RA de Boer","year":"2019","unstructured":"\u2022\u2022 de Boer RA, Meijers WC, van der Meer P, van Veldhuisen DJ. Cancer and heart disease: associations and relations. Eur J Heart Fail. 2019;21(12):1515\u201325. https:\/\/doi.org\/10.1002\/ejhf.1539 Emerging evidence of cancer and heart diseases interplay.","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"812_CR88","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1093\/cvr\/cvz035","volume":"115","author":"WC Meijers","year":"2019","unstructured":"\u2022\u2022 Meijers WC, de Boer RA. Common risk factors for heart failure and cancer. Cardiovasc Res. 2019;115(5):844\u201353. https:\/\/doi.org\/10.1093\/cvr\/cvz035 Highlighting of common risk factors shared between heart failure and cancer.","journal-title":"Cardiovasc Res"},{"issue":"5","key":"812_CR89","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/ejhf.1165","volume":"20","author":"P Ameri","year":"2018","unstructured":"\u2022 Ameri P, Canepa M, Anker MS, Belenkov Y, Bergler-Klein J, Cohen-Solal A, et al. Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge. Eur J Heart Fail. 2018;20(5):879\u201387. https:\/\/doi.org\/10.1002\/ejhf.1165 Guideline of cancer diagnosis in patients with heart failure.","journal-title":"Eur J Heart Fail"},{"issue":"43","key":"812_CR90","doi-asserted-by":"publisher","first-page":"32841","DOI":"10.1074\/jbc.M513087200","volume":"281","author":"B DeBosch","year":"2006","unstructured":"DeBosch B, Sambandam N, Weinheimer C, Courtois M, Muslin AJ. Akt2 regulates cardiac metabolism and cardiomyocyte survival. J Biol Chem. 2006;281(43):32841\u201351. https:\/\/doi.org\/10.1074\/jbc.M513087200.","journal-title":"J Biol Chem"},{"issue":"7","key":"812_CR91","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1161\/CIRCRESAHA.116.306206","volume":"118","author":"C Riehle","year":"2016","unstructured":"Riehle C, Abel ED. Insulin signaling and heart failure. Circ Res. 2016;118(7):1151\u201369. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.306206.","journal-title":"Circ Res"},{"issue":"16","key":"812_CR92","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1038\/onc.2008.25","volume":"27","author":"DN Gross","year":"2008","unstructured":"Gross DN, van den Heuvel AP, Birnbaum MJ. The role of FoxO in the regulation of metabolism. Oncogene. 2008;27(16):2320\u201336. https:\/\/doi.org\/10.1038\/onc.2008.25.","journal-title":"Oncogene."},{"issue":"2","key":"812_CR93","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/nrm3507","volume":"14","author":"A Eijkelenboom","year":"2013","unstructured":"Eijkelenboom A, Burgering BM. FOXOs: signalling integrators for homeostasis maintenance. Nat Rev Mol Cell Biol. 2013;14(2):83\u201397. https:\/\/doi.org\/10.1038\/nrm3507.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"13","key":"812_CR94","doi-asserted-by":"publisher","first-page":"4265","DOI":"10.1074\/jbc.RA119.011571","volume":"295","author":"P Xia","year":"2020","unstructured":"\u2022 Xia P, Chen J, Liu Y, Fletcher M, Jensen BC, Cheng Z. Doxorubicin induces cardiomyocyte apoptosis and atrophy through cyclin-dependent kinase 2-mediated activation of forkhead box O1. J Biol Chem. 2020;295(13):4265\u201376. https:\/\/doi.org\/10.1074\/jbc.RA119.011571 New study that indicates FOXO1 as a potential target in DOXO-induced cardiotoxicity.","journal-title":"J Biol Chem"},{"key":"812_CR95","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.yjmcc.2019.12.007","volume":"138","author":"J Oh","year":"2020","unstructured":"Oh J, Lee BS, Lim G, Lim H, Lee CJ, Park S, et al. Atorvastatin protects cardiomyocyte from doxorubicin toxicity by modulating survivin expression through FOXO1 inhibition. J Mol Cell Cardiol. 2020;138:244\u201355. https:\/\/doi.org\/10.1016\/j.yjmcc.2019.12.007.","journal-title":"J Mol Cell Cardiol"},{"issue":"13","key":"812_CR96","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1056\/NEJMra072139","volume":"358","author":"JA Hill","year":"2008","unstructured":"Hill JA, Olson EN. Cardiac plasticity. N Engl J Med. 2008;358(13):1370\u201380. https:\/\/doi.org\/10.1056\/NEJMra072139.","journal-title":"N Engl J Med"},{"issue":"1","key":"812_CR97","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s13539-011-0051-5","volume":"3","author":"MA Honors","year":"2012","unstructured":"Honors MA, Kinzig KP. The role of insulin resistance in the development of muscle wasting during cancer cachexia. J Cachexia Sarcopenia Muscle. 2012;3(1):5\u201311. https:\/\/doi.org\/10.1007\/s13539-011-0051-5.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"10","key":"812_CR98","doi-asserted-by":"publisher","first-page":"e93098","DOI":"10.1172\/jci.insight.93098","volume":"2","author":"JT Thackeray","year":"2017","unstructured":"\u2022\u2022 Thackeray JT, Pietzsch S, Stapel B, Ricke-Hoch M, Lee CW, Bankstahl JP, et al. Insulin supplementation attenuates cancer-induced cardiomyopathy and slows tumor disease progression. JCI Insight. 2017;2(10):e93098. https:\/\/doi.org\/10.1172\/jci.insight.93098 Important evidence that describes the effect of cancer on cardiac insulin signalling.","journal-title":"JCI Insight"},{"issue":"10","key":"812_CR99","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1006\/jmcc.2002.2068","volume":"34","author":"Y Taniyama","year":"2002","unstructured":"Taniyama Y, Walsh K. Elevated myocardial Akt signaling ameliorates doxorubicin-induced congestive heart failure and promotes heart growth. J Mol Cell Cardiol. 2002;34(10):1241\u20137. https:\/\/doi.org\/10.1006\/jmcc.2002.2068.","journal-title":"J Mol Cell Cardiol"},{"issue":"1","key":"812_CR100","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1006\/phrs.1999.0568","volume":"41","author":"OA Al-Shabanah","year":"2000","unstructured":"Al-Shabanah OA, El-Kashef HA, Badary OA, Al-Bekairi AM, Elmazar MM. Effect of streptozotocin-induced hyperglycaemia on intravenous pharmacokinetics and acute cardiotoxicity of doxorubicin in rats. Pharmacol Res. 2000;41(1):31\u20137. https:\/\/doi.org\/10.1006\/phrs.1999.0568.","journal-title":"Pharmacol Res"},{"issue":"9","key":"812_CR101","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1089\/ars.2007.1714","volume":"9","author":"M Kurtoglu","year":"2007","unstructured":"Kurtoglu M, Maher JC, Lampidis TJ. Differential toxic mechanisms of 2-deoxy-D-glucose versus 2-fluorodeoxy-D-glucose in hypoxic and normoxic tumor cells. Antioxid Redox Signal. 2007;9(9):1383\u201390. https:\/\/doi.org\/10.1089\/ars.2007.1714.","journal-title":"Antioxid Redox Signal"},{"issue":"1","key":"812_CR102","doi-asserted-by":"publisher","first-page":"234","DOI":"10.3390\/ijms21010234","volume":"21","author":"B Pajak","year":"2019","unstructured":"Pajak B, Siwiak E, Soltyka M, Priebe A, Zielinski R, Fokt I, et al. 2-Deoxy-d-glucose and its analogs: from diagnostic to therapeutic agents. Int J Mol Sci. 2019;21(1):234. https:\/\/doi.org\/10.3390\/ijms21010234.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"812_CR103","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/0008-5472.can-03-3294","volume":"64","author":"G Maschek","year":"2004","unstructured":"Maschek G, Savaraj N, Priebe W, Braunschweiger P, Hamilton K, Tidmarsh GF, et al. 2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res. 2004;64(1):31\u20134. https:\/\/doi.org\/10.1158\/0008-5472.can-03-3294.","journal-title":"Cancer Res"},{"issue":"25","key":"812_CR104","doi-asserted-by":"publisher","first-page":"21993","DOI":"10.1074\/jbc.M111.225805","volume":"286","author":"K Chen","year":"2011","unstructured":"Chen K, Xu X, Kobayashi S, Timm D, Jepperson T, Liang Q. Caloric restriction mimetic 2-deoxyglucose antagonizes doxorubicin-induced cardiomyocyte death by multiple mechanisms. J Biol Chem. 2011;286(25):21993\u20132006. https:\/\/doi.org\/10.1074\/jbc.M111.225805.","journal-title":"J Biol Chem"},{"issue":"4","key":"812_CR105","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1158\/0008-5472.CAN-12-2072","volume":"73","author":"J Cao","year":"2013","unstructured":"Cao J, Cui S, Li S, Du C, Tian J, Wan S, et al. Targeted cancer therapy with a 2-deoxyglucose-based adriamycin complex. Cancer Res. 2013;73(4):1362\u201373. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-2072.","journal-title":"Cancer Res"},{"issue":"6","key":"812_CR106","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1111\/jcmm.13053","volume":"21","author":"I Lekli","year":"2017","unstructured":"Lekli I, Haines DD, Balla G, Tosaki A. Autophagy: an adaptive physiological countermeasure to cellular senescence and ischaemia\/reperfusion-associated cardiac arrhythmias. J Cell Mol Med. 2017;21(6):1058\u201372. https:\/\/doi.org\/10.1111\/jcmm.13053.","journal-title":"J Cell Mol Med"},{"issue":"1","key":"812_CR107","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.mam.2011.09.001","volume":"33","author":"AM Cuervo","year":"2012","unstructured":"Cuervo AM, Macian F. Autophagy, nutrition and immunology. Mol Asp Med. 2012;33(1):2\u201313. https:\/\/doi.org\/10.1016\/j.mam.2011.09.001.","journal-title":"Mol Asp Med"},{"issue":"3","key":"812_CR108","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1093\/cvr\/cvs282","volume":"96","author":"T Kawaguchi","year":"2012","unstructured":"Kawaguchi T, Takemura G, Kanamori H, Takeyama T, Watanabe T, Morishita K, et al. Prior starvation mitigates acute doxorubicin cardiotoxicity through restoration of autophagy in affected cardiomyocytes. Cardiovasc Res. 2012;96(3):456\u201365. https:\/\/doi.org\/10.1093\/cvr\/cvs282.","journal-title":"Cardiovasc Res"},{"issue":"12","key":"812_CR109","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.1016\/j.cellsig.2014.08.019","volume":"26","author":"D Heras-Sandoval","year":"2014","unstructured":"Heras-Sandoval D, Perez-Rojas JM, Hernandez-Damian J, Pedraza-Chaverri J. The role of PI3K\/AKT\/mTOR pathway in the modulation of autophagy and the clearance of protein aggregates in neurodegeneration. Cell Signal. 2014;26(12):2694\u2013701. https:\/\/doi.org\/10.1016\/j.cellsig.2014.08.019.","journal-title":"Cell Signal"},{"issue":"2","key":"812_CR110","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/ncb2152","volume":"13","author":"J Kim","year":"2011","unstructured":"Kim J, Kundu M, Viollet B, Guan KL. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol. 2011;13(2):132\u201341. https:\/\/doi.org\/10.1038\/ncb2152.","journal-title":"Nat Cell Biol"},{"issue":"2","key":"812_CR111","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","volume":"149","author":"M Laplante","year":"2012","unstructured":"Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149(2):274\u201393. https:\/\/doi.org\/10.1016\/j.cell.2012.03.017.","journal-title":"Cell."},{"issue":"3\u20134","key":"812_CR112","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.ejps.2010.07.015","volume":"41","author":"DR Barpe","year":"2010","unstructured":"Barpe DR, Rosa DD, Froehlich PE. Pharmacokinetic evaluation of doxorubicin plasma levels in normal and overweight patients with breast cancer and simulation of dose adjustment by different indexes of body mass. Eur J Pharm Sci : official journal of the European Federation for Pharmaceutical Sciences. 2010;41(3\u20134):458\u201363. https:\/\/doi.org\/10.1016\/j.ejps.2010.07.015.","journal-title":"Eur J Pharm Sci : official journal of the European Federation for Pharmaceutical Sciences"},{"issue":"4","key":"812_CR113","doi-asserted-by":"publisher","first-page":"BSR20170982","DOI":"10.1042\/BSR20170982","volume":"38","author":"Y Li","year":"2018","unstructured":"Li Y, Wang Y, Zou M, Chen C, Chen Y, Xue R, et al. AMPK blunts chronic heart failure by inhibiting autophagy. Biosci Rep. 2018;38(4):BSR20170982. https:\/\/doi.org\/10.1042\/BSR20170982.","journal-title":"Biosci Rep"},{"issue":"4","key":"812_CR114","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1152\/physiol.00010.2011","volume":"26","author":"C Canto","year":"2011","unstructured":"Canto C, Auwerx J. Calorie restriction: is AMPK a key sensor and effector? Physiology (Bethesda). 2011;26(4):214\u201324. https:\/\/doi.org\/10.1152\/physiol.00010.2011.","journal-title":"Physiology (Bethesda)"},{"issue":"1","key":"812_CR115","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.taap.2007.07.018","volume":"225","author":"MS Mitra","year":"2007","unstructured":"Mitra MS, Donthamsetty S, White B, Latendresse JR, Mehendale HM. Mechanism of protection of moderately diet restricted rats against doxorubicin-induced acute cardiotoxicity. Toxicol Appl Pharmacol. 2007;225(1):90\u2013101. https:\/\/doi.org\/10.1016\/j.taap.2007.07.018.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"10","key":"812_CR116","doi-asserted-by":"publisher","first-page":"e47351","DOI":"10.1371\/journal.pone.0047351","volume":"7","author":"X Lv","year":"2012","unstructured":"Lv X, Yu X, Wang Y, Wang F, Li H, Wang Y, et al. Berberine inhibits doxorubicin-triggered cardiomyocyte apoptosis via attenuating mitochondrial dysfunction and increasing Bcl-2 expression. PLoS One. 2012;7(10):e47351. https:\/\/doi.org\/10.1371\/journal.pone.0047351.","journal-title":"PLoS One"},{"issue":"1","key":"812_CR117","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s12944-019-1151-z","volume":"18","author":"MJ Trites","year":"2019","unstructured":"Trites MJ, Clugston RD. The role of adipose triglyceride lipase in lipid and glucose homeostasis: lessons from transgenic mice. Lipids Health Dis. 2019;18(1):204. https:\/\/doi.org\/10.1186\/s12944-019-1151-z.","journal-title":"Lipids Health Dis"},{"issue":"1","key":"812_CR118","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1038\/s41598-018-37862-3","volume":"9","author":"CS Abdullah","year":"2019","unstructured":"\u2022\u2022 Abdullah CS, Alam S, Aishwarya R, Miriyala S, Bhuiyan MAN, Panchatcharam M, et al. Doxorubicin-induced cardiomyopathy associated with inhibition of autophagic degradation process and defects in mitochondrial respiration. Sci Rep. 2019;9(1):2002. https:\/\/doi.org\/10.1038\/s41598-018-37862-3 Time course study of DOXO treatment showing impairment of autophagy, mitochondrial dynamics, and bioenergetics in both acute and chronic mouse models of DOXO- associated cardiomyopathy.","journal-title":"Sci Rep"},{"key":"812_CR119","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.yjmcc.2019.06.005","volume":"133","author":"P Wang","year":"2019","unstructured":"Wang P, Wang L, Lu J, Hu Y, Wang Q, Li Z, et al. SESN2 protects against doxorubicin-induced cardiomyopathy via rescuing mitophagy and improving mitochondrial function. J Mol Cell Cardiol. 2019;133:125\u201337. https:\/\/doi.org\/10.1016\/j.yjmcc.2019.06.005.","journal-title":"J Mol Cell Cardiol"},{"issue":"51","key":"812_CR120","doi-asserted-by":"publisher","first-page":"E5537","DOI":"10.1073\/pnas.1414665111","volume":"111","author":"R Dhingra","year":"2014","unstructured":"Dhingra R, Margulets V, Chowdhury SR, Thliveris J, Jassal D, Fernyhough P, et al. Bnip3 mediates doxorubicin-induced cardiac myocyte necrosis and mortality through changes in mitochondrial signaling. Proc Natl Acad Sci U S A. 2014;111(51):E5537\u201344. https:\/\/doi.org\/10.1073\/pnas.1414665111.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"812_CR121","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.yjmcc.2014.01.002","volume":"71","author":"A Sun","year":"2014","unstructured":"Sun A, Cheng Y, Zhang Y, Zhang Q, Wang S, Tian S, et al. Aldehyde dehydrogenase 2 ameliorates doxorubicin-induced myocardial dysfunction through detoxification of 4-HNE and suppression of autophagy. J Mol Cell Cardiol. 2014;71:92\u2013104. https:\/\/doi.org\/10.1016\/j.yjmcc.2014.01.002.","journal-title":"J Mol Cell Cardiol"},{"issue":"1","key":"812_CR122","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.pharmthera.2011.05.008","volume":"132","author":"Y Zhang","year":"2011","unstructured":"Zhang Y, Ren J. ALDH2 in alcoholic heart diseases: molecular mechanism and clinical implications. Pharmacol Ther. 2011;132(1):86\u201395. https:\/\/doi.org\/10.1016\/j.pharmthera.2011.05.008.","journal-title":"Pharmacol Ther"},{"issue":"5895","key":"812_CR123","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1126\/science.1158554","volume":"321","author":"CH Chen","year":"2008","unstructured":"Chen CH, Budas GR, Churchill EN, Disatnik MH, Hurley TD, Mochly-Rosen D. Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart. Science. 2008;321(5895):1493\u20135. https:\/\/doi.org\/10.1126\/science.1158554.","journal-title":"Science."},{"issue":"14","key":"812_CR124","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1161\/CIRCULATIONAHA.108.823799","volume":"119","author":"TA Doser","year":"2009","unstructured":"Doser TA, Turdi S, Thomas DP, Epstein PN, Li SY, Ren J. Transgenic overexpression of aldehyde dehydrogenase-2 rescues chronic alcohol intake-induced myocardial hypertrophy and contractile dysfunction. Circulation. 2009;119(14):1941\u20139. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.108.823799.","journal-title":"Circulation."},{"issue":"4","key":"812_CR125","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.bbadis.2015.12.014","volume":"1862","author":"W Ge","year":"2016","unstructured":"Ge W, Yuan M, Ceylan AF, Wang X, Ren J. Mitochondrial aldehyde dehydrogenase protects against doxorubicin cardiotoxicity through a transient receptor potential channel vanilloid 1-mediated mechanism. Biochim Biophys Acta. 2016;1862(4):622\u201334. https:\/\/doi.org\/10.1016\/j.bbadis.2015.12.014.","journal-title":"Biochim Biophys Acta"},{"issue":"10","key":"812_CR126","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/j.freeradbiomed.2008.08.008","volume":"45","author":"S Cardoso","year":"2008","unstructured":"Cardoso S, Santos RX, Carvalho C, Correia S, Pereira GC, Pereira SS, et al. Doxorubicin increases the susceptibility of brain mitochondria to Ca(2+)-induced permeability transition and oxidative damage. Free Radic Biol Med. 2008;45(10):1395\u2013402. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2008.08.008.","journal-title":"Free Radic Biol Med"},{"issue":"10","key":"812_CR127","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.3390\/ijms17101680","volume":"17","author":"JH Park","year":"2016","unstructured":"Park JH, Choi SH, Kim H, Ji ST, Jang WB, Kim JH, et al. Doxorubicin regulates autophagy signals via accumulation of cytosolic Ca(2+) in human cardiac progenitor cells. Int J Mol Sci. 2016;17(10):1680. https:\/\/doi.org\/10.3390\/ijms17101680.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"812_CR128","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.ceca.2011.04.001","volume":"50","author":"JP Decuypere","year":"2011","unstructured":"Decuypere JP, Bultynck G, Parys JB. A dual role for Ca(2+) in autophagy regulation. Cell Calcium. 2011;50(3):242\u201350. https:\/\/doi.org\/10.1016\/j.ceca.2011.04.001.","journal-title":"Cell Calcium"},{"issue":"2","key":"812_CR129","doi-asserted-by":"publisher","first-page":"C235","DOI":"10.1152\/ajpcell.00079.2019","volume":"317","author":"S Pandey","year":"2019","unstructured":"Pandey S, Kuo WW, Shen CY, Yeh YL, Ho TJ, Chen RJ, et al. Insulin-like growth factor II receptor-alpha is a novel stress-inducible contributor to cardiac damage underpinning doxorubicin-induced oxidative stress and perturbed mitochondrial autophagy. Am J Phys Cell Phys. 2019;317(2):C235\u2013C43. https:\/\/doi.org\/10.1152\/ajpcell.00079.2019.","journal-title":"Am J Phys Cell Phys"},{"issue":"6","key":"812_CR130","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.2337\/db10-0351","volume":"60","author":"Z Xie","year":"2011","unstructured":"Xie Z, Lau K, Eby B, Lozano P, He C, Pennington B, et al. Improvement of cardiac functions by chronic metformin treatment is associated with enhanced cardiac autophagy in diabetic OVE26 mice. Diabetes. 2011;60(6):1770\u20138. https:\/\/doi.org\/10.2337\/db10-0351.","journal-title":"Diabetes."},{"key":"812_CR131","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.bcp.2018.03.013","volume":"152","author":"C Xu","year":"2018","unstructured":"Xu C, Wang W, Zhong J, Lei F, Xu N, Zhang Y, et al. Canagliflozin exerts anti-inflammatory effects by inhibiting intracellular glucose metabolism and promoting autophagy in immune cells. Biochem Pharmacol. 2018;152:45\u201359. https:\/\/doi.org\/10.1016\/j.bcp.2018.03.013.","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"812_CR132","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jacbts.2018.07.006","volume":"3","author":"S Verma","year":"2018","unstructured":"\u2022 Verma S, Rawat S, Ho KL, Wagg CS, Zhang L, Teoh H, et al. Empagliflozin increases cardiac energy production in diabetes: novel translational insights into the heart failure benefits of SGLT2 inhibitors. JACC Basic Transl Sci. 2018;3(5):575\u201387. https:\/\/doi.org\/10.1016\/j.jacbts.2018.07.006 Recent study suggesting the beneficial impact on cardiac function of Empagliflozin, a new antidiabetic class. The authors evaluated cardiac energy production and substrate use in diabetic mice treated with Empagliflozin.","journal-title":"JACC Basic Transl Sci"},{"issue":"3","key":"812_CR133","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s10557-017-6734-1","volume":"31","author":"N Hammoudi","year":"2017","unstructured":"Hammoudi N, Jeong D, Singh R, Farhat A, Komajda M, Mayoux E, et al. Empagliflozin improves left ventricular diastolic dysfunction in a genetic model of type 2 diabetes. Cardiovasc Drugs Ther. 2017;31(3):233\u201346. https:\/\/doi.org\/10.1007\/s10557-017-6734-1.","journal-title":"Cardiovasc Drugs Ther"},{"key":"812_CR134","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1038\/ncomms2266","volume":"3","author":"FH Karlsson","year":"2012","unstructured":"Karlsson FH, Fak F, Nookaew I, Tremaroli V, Fagerberg B, Petranovic D, et al. Symptomatic atherosclerosis is associated with an altered gut metagenome. Nat Commun. 2012;3:1245. https:\/\/doi.org\/10.1038\/ncomms2266.","journal-title":"Nat Commun"},{"issue":"9","key":"812_CR135","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1161\/CIRCRESAHA.115.306807","volume":"117","author":"J Fu","year":"2015","unstructured":"Fu J, Bonder MJ, Cenit MC, Tigchelaar EF, Maatman A, Dekens JA, et al. The gut microbiome contributes to a substantial proportion of the variation in blood lipids. Circ Res. 2015;117(9):817\u201324. https:\/\/doi.org\/10.1161\/CIRCRESAHA.115.306807.","journal-title":"Circ Res"},{"issue":"1","key":"812_CR136","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nrcardio.2017.120","volume":"15","author":"FZ Marques","year":"2018","unstructured":"Marques FZ, Mackay CR, Kaye DM. Beyond gut feelings: how the gut microbiota regulates blood pressure. Nat Rev Cardiol. 2018;15(1):20\u201332. https:\/\/doi.org\/10.1038\/nrcardio.2017.120.","journal-title":"Nat Rev Cardiol"},{"issue":"3","key":"812_CR137","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1161\/CIRCRESAHA.116.305360","volume":"116","author":"WH Tang","year":"2015","unstructured":"Tang WH, Wang Z, Kennedy DJ, Wu Y, Buffa JA, Agatisa-Boyle B, et al. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ Res. 2015;116(3):448\u201355. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.305360.","journal-title":"Circ Res"},{"issue":"7122","key":"812_CR138","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1038\/nature05414","volume":"444","author":"PJ Turnbaugh","year":"2006","unstructured":"Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444(7122):1027\u201331. https:\/\/doi.org\/10.1038\/nature05414.","journal-title":"Nature."},{"issue":"7216","key":"812_CR139","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1038\/nature07336","volume":"455","author":"L Wen","year":"2008","unstructured":"Wen L, Ley RE, Volchkov PY, Stranges PB, Avanesyan L, Stonebraker AC, et al. Innate immunity and intestinal microbiota in the development of type 1 diabetes. Nature. 2008;455(7216):1109\u201313. https:\/\/doi.org\/10.1038\/nature07336.","journal-title":"Nature."},{"issue":"7418","key":"812_CR140","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nature11450","volume":"490","author":"J Qin","year":"2012","unstructured":"Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490(7418):55\u201360. https:\/\/doi.org\/10.1038\/nature11450.","journal-title":"Nature."},{"issue":"3","key":"812_CR141","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41569-018-0108-7","volume":"16","author":"WHW Tang","year":"2019","unstructured":"Tang WHW, Li DY, Hazen SL. Dietary metabolism, the gut microbiome, and heart failure. Nat Rev Cardiol. 2019;16(3):137\u201354. https:\/\/doi.org\/10.1038\/s41569-018-0108-7.","journal-title":"Nat Rev Cardiol"},{"key":"812_CR142","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13059-015-0646-9","volume":"16","author":"A Zhu","year":"2015","unstructured":"Zhu A, Sunagawa S, Mende DR, Bork P. Inter-individual differences in the gene content of human gut bacterial species. Genome Biol. 2015;16:82. https:\/\/doi.org\/10.1186\/s13059-015-0646-9.","journal-title":"Genome Biol"},{"issue":"7415","key":"812_CR143","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/nature11552","volume":"489","author":"V Tremaroli","year":"2012","unstructured":"Tremaroli V, Backhed F. Functional interactions between the gut microbiota and host metabolism. Nature. 2012;489(7415):242\u20139. https:\/\/doi.org\/10.1038\/nature11552.","journal-title":"Nature."},{"key":"812_CR144","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1146\/annurev-med-060513-093205","volume":"66","author":"JM Brown","year":"2015","unstructured":"Brown JM, Hazen SL. The gut microbial endocrine organ: bacterially derived signals driving cardiometabolic diseases. Annu Rev Med. 2015;66:343\u201359. https:\/\/doi.org\/10.1146\/annurev-med-060513-093205.","journal-title":"Annu Rev Med"},{"key":"812_CR145","doi-asserted-by":"publisher","first-page":"851717","DOI":"10.1155\/2012\/851717","volume":"2012","author":"L Li","year":"2012","unstructured":"Li L, Hua Y, Ren J. Short-chain fatty acid propionate alleviates Akt2 knockout-induced myocardial contractile dysfunction. Exp Diabetes Res. 2012;2012:851717. https:\/\/doi.org\/10.1155\/2012\/851717.","journal-title":"Exp Diabetes Res"},{"issue":"31","key":"812_CR146","doi-asserted-by":"publisher","first-page":"28930","DOI":"10.1074\/jbc.M303113200","volume":"278","author":"CL Antos","year":"2003","unstructured":"Antos CL, McKinsey TA, Dreitz M, Hollingsworth LM, Zhang CL, Schreiber K, et al. Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors. J Biol Chem. 2003;278(31):28930\u20137. https:\/\/doi.org\/10.1074\/jbc.M303113200.","journal-title":"J Biol Chem"},{"issue":"3","key":"812_CR147","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1093\/cvr\/cvn215","volume":"80","author":"P Gallo","year":"2008","unstructured":"Gallo P, Latronico MV, Gallo P, Grimaldi S, Borgia F, Todaro M, et al. Inhibition of class I histone deacetylase with an apicidin derivative prevents cardiac hypertrophy and failure. Cardiovasc Res. 2008;80(3):416\u201324. https:\/\/doi.org\/10.1093\/cvr\/cvn215.","journal-title":"Cardiovasc Res"},{"issue":"10","key":"812_CR148","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1096\/fj.08-108548","volume":"22","author":"A Granger","year":"2008","unstructured":"Granger A, Abdullah I, Huebner F, Stout A, Wang T, Huebner T, et al. Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice. FASEB J. 2008;22(10):3549\u201360. https:\/\/doi.org\/10.1096\/fj.08-108548.","journal-title":"FASEB J"},{"issue":"22","key":"812_CR149","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1161\/CIRCULATIONAHA.106.625467","volume":"113","author":"Y Kong","year":"2006","unstructured":"Kong Y, Tannous P, Lu G, Berenji K, Rothermel BA, Olson EN, et al. Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy. Circulation. 2006;113(22):2579\u201388. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.625467.","journal-title":"Circulation."},{"issue":"1","key":"812_CR150","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10637-017-0500-x","volume":"36","author":"L Moyal","year":"2018","unstructured":"Moyal L, Goldfeiz N, Gorovitz B, Rephaeli A, Tal E, Tarasenko N, et al. AN-7, a butyric acid prodrug, sensitizes cutaneous T-cell lymphoma cell lines to doxorubicin via inhibition of DNA double strand breaks repair. Investig New Drugs. 2018;36(1):1\u20139. https:\/\/doi.org\/10.1007\/s10637-017-0500-x.","journal-title":"Investig New Drugs"},{"issue":"11","key":"812_CR151","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1038\/sj.bjc.6603781","volume":"96","author":"A Rephaeli","year":"2007","unstructured":"Rephaeli A, Waks-Yona S, Nudelman A, Tarasenko I, Tarasenko N, Phillips DR, et al. Anticancer prodrugs of butyric acid and formaldehyde protect against doxorubicin-induced cardiotoxicity. Br J Cancer. 2007;96(11):1667\u201374. https:\/\/doi.org\/10.1038\/sj.bjc.6603781.","journal-title":"Br J Cancer"},{"issue":"1","key":"812_CR152","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1007\/s10637-010-9542-z","volume":"30","author":"N Tarasenko","year":"2012","unstructured":"Tarasenko N, Kessler-Icekson G, Boer P, Inbal A, Schlesinger H, Phillips DR, et al. The histone deacetylase inhibitor butyroyloxymethyl diethylphosphate (AN-7) protects normal cells against toxicity of anticancer agents while augmenting their anticancer activity. Investig New Drugs. 2012;30(1):130\u201343. https:\/\/doi.org\/10.1007\/s10637-010-9542-z.","journal-title":"Investig New Drugs"},{"issue":"4","key":"812_CR153","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/ejhf.1439","volume":"21","author":"M Russo","year":"2019","unstructured":"\u2022 Russo M, Guida F, Paparo L, Trinchese G, Aitoro R, Avagliano C, et al. The novel butyrate derivative phenylalanine-butyramide protects from doxorubicin-induced cardiotoxicity. Eur J Heart Fail. 2019;21(4):519\u201328. https:\/\/doi.org\/10.1002\/ejhf.1439 Butyrate-derived molecule prevents cardiac mitochondria dysfunction in the heart.","journal-title":"Eur J Heart Fail"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-020-00812-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11864-020-00812-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-020-00812-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T22:46:25Z","timestamp":1613688385000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11864-020-00812-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":153,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["812"],"URL":"https:\/\/doi.org\/10.1007\/s11864-020-00812-1","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"20 December 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Michele Russo declares that he has no conflict of interest.Angela Della Sala declares that she has no conflict of interest.Carlo Gabriele Tocchetti has received compensation from Alere for service as a consultant and is listed as an inventor on 2 heart failure patents.Paolo Ettore Porporato declares that he has no conflict of interest.Alessandra Ghigo is a co-founder and stakeholder of Kither Biotech, a pharmaceutical product company focused on respiratory medicine not in conflict with statements made in this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"18"}}